Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (291-300 of 686) with videos related to

Pageof 69
Sort By:
Cancer|October 20, 2011
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situSoley Bayraktar, Nisreen Elsayegh, Angelica M Gutierrez Barrera, et al.
Breast Cancer Research : BCR|August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerNatalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer|January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancersJibran Ahmed, Filip Janku, Daniel D Karp, et al.
JAMA Network Open|May 6, 2024
KRAS Allelic Variants in Biliary Tract CancersGordon Taylor Moffat, Zishuo Ian Hu, Funda Meric-Bernstam, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
American Journal of Surgery|May 12, 2009
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgeryJudy C Boughey, Farzin Goravanchi, Ronald N Parris, et al.
Cancer|May 2, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancerMehmet Altan, Janet Tu, Denái R Milton, et al.
NPJ Breast Cancer|August 11, 2023
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecanMing Zhao, Timothy P DiPeri, Maria Gabriela Raso, et al.
Molecular Cancer Therapeutics|April 15, 2011
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancerAna M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, et al.
Breast Cancer Research and Treatment|February 26, 2009
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast densityWei Tse Yang, Michael T Lewis, Kenneth Hess, et al.
Pageof 69

Showing results (291-300 of 686) with videos related to

Sort By:
Pageof 69
Cancer|October 20, 2011
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situSoley Bayraktar, Nisreen Elsayegh, Angelica M Gutierrez Barrera, et al.
Breast Cancer Research : BCR|August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerNatalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer|January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancersJibran Ahmed, Filip Janku, Daniel D Karp, et al.
JAMA Network Open|May 6, 2024
KRAS Allelic Variants in Biliary Tract CancersGordon Taylor Moffat, Zishuo Ian Hu, Funda Meric-Bernstam, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
American Journal of Surgery|May 12, 2009
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgeryJudy C Boughey, Farzin Goravanchi, Ronald N Parris, et al.
Cancer|May 2, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancerMehmet Altan, Janet Tu, Denái R Milton, et al.
NPJ Breast Cancer|August 11, 2023
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecanMing Zhao, Timothy P DiPeri, Maria Gabriela Raso, et al.
Molecular Cancer Therapeutics|April 15, 2011
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancerAna M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, et al.
Breast Cancer Research and Treatment|February 26, 2009
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast densityWei Tse Yang, Michael T Lewis, Kenneth Hess, et al.
Pageof 69